Publications by authors named "Serina Deeba"
Article Synopsis
- This study focused on the use of oral anticoagulants (OACs) like apixaban and warfarin for preventing recurrent venous thromboembolism (VTE) after hospital discharge, using data from July 2016 to December 2022.
- Of the 19,303 patients examined, around 70% continued their anticoagulant therapy after leaving the hospital, but over half either switched medications or stopped taking them within six months.
- The study found lower rates of discontinuation and recurrent VTE among patients using apixaban compared to those using warfarin, suggesting apixaban may be more effective for long-term management.
Background Pulmonary thrombosis and thromboembolism play a significant role in the physiologic derangements seen in COVID-19 acute respiratory failure. The effect of thrombolysis with tenecteplase on patient outcomes is unknown. Methods We conducted a randomized, controlled, double-blind, phase II trial comparing tenecteplase versus placebo in patients with COVID-19 acute respiratory failure (NCT04505592).
View Article and Find Full Text PDFBackground: Venous thromboembolism (VTE) is a major public health condition that renders patients at risk of recurrent events, which significantly increases their morbidity, mortality, and health care costs. Apart from warfarin, direct oral anticoagulants, such as apixaban, dabigatran, or rivaroxaban, are approved for VTE treatment. Cardiovascular drugs are largely impacted by formulary restrictions; however, the impact on oral anticoagulants (including warfarin and direct oral anticoagulants) in VTE has not been well studied.
View Article and Find Full Text PDF